pharmaceuticals PM market analysis — 2026-09-20

Pharmaceutical supply chains are shifting away from lowest-cost sourcing toward resilience, even as reliance on manufacturing hubs in China and India persists, according to Air Cargo Week. BioPharm International reports that tariff exposure is adding pressure on companies to expand or establish production capacity within the United States, a move that would raise operating costs in exchange for reduced trade risk.

On the clinical side, BioPharma Dive’s outlook points to a run of late-stage trial readouts across major therapeutic areas that could reshape expectations for leading drug programmes. IQVIA’s analysis cautions that the market reaction to these results is uneven, with the effect on valuations depending on development stage and the direction of the outcome rather than being automatic.

Taken together, the sector faces a split picture: supply chain adjustments are a slow, structural response to tariff and geopolitical pressure, while clinical catalysts carry more immediate but unpredictable consequences. Neither strand points clearly toward broad upside or downside for the sector as a whole.